Clinical trial · Interventional
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06979076CI-TRIAL-00095895not yet recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CLL (Chronic Lymphocytic Leukemia) | Chronic Lymphocytic Leukemia | ALIAS | 0.85 |
| SLL (Small Lymphocytic Lymphoma) | Small Lymphocytic Lymphoma | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MS-553, DS1 | Drug | — | UNRESOLVED |
| MS-553, DS2 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MS-553, dose schedule 1 (DS1)
- interventionNames
- Drug: MS-553, DS1
- type
- EXPERIMENTAL
- label
- MS-553, dose schedule 2 (DS2)
- interventionNames
- Drug: MS-553, DS2
Primary outcomes (1)
- measure
- The occurrence of AEs and SAEs, with abnormal laboratory tests results, abnormal physical examination findings, abnormal vital signs, and abnormal ECG readings
- timeFrame
- Through study completion, an average of 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 years or older. 2. Diagnosis of CLL or SLL: 1. History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and 2. Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.- Exclusion Criteria: 1. Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma. 2. Active and uncontrolled autoimmune cytopenia(s).
References
Publications (0)
Data not yet available
No reference posted for this study.